Tosoian Jeffrey J, Ludwig Wesley, Sopko Nikolai, Mullins Jeffrey K, Matlaga Brian R
Department of Urology, The James Buchanan Brady Urological Institute, The Johns Hopkins University School of Medicine , Johns Hopkins Hospital, Baltimore, Maryland.
J Endourol. 2015 Apr;29(4):406-9. doi: 10.1089/end.2014.0435. Epub 2014 Nov 7.
Ureteroscopy (URS) is a common treatment for patients with stone disease. One of the disadvantages of this approach is the great capital expense associated with the purchase and repair of endoscopic equipment. In some cases, these costs can outpace revenues and lead to an unprofitable and unsustainable enterprise. We sought to characterize the profitability of our URS program when accounting for endoscope maintenance and repair costs.
We identified all URS cases performed at a single hospital during fiscal year 2013 (FY2013). Charges, collection rates, and fixed and variable costs including annual equipment repair costs were obtained. The net margin and break-even point of URS were derived on a per-case basis.
For 190 cases performed in FY2013, total endoscope repair costs totaled $115,000, resulting in an average repair cost of $605 per case. The vast majority of cases (94.2%) were conducted in the outpatient setting, which generated a net margin of $659 per case, while inpatient cases yielded a net loss of $455. URS was ultimately associated with a net positive margin approaching $600 per case. On break-even analysis, URS remained profitable until repair costs reached $1200 per case.
Based on these findings, an established URS program can sustain profitability even with large equipment repair costs. Nonetheless, our findings serve to emphasize the importance of controlling costs, particularly in the current setting of decreasing reimbursement. A multifaceted approach, based on improving endoscope durability and exploring digital and disposable platforms, will be critical in maintaining the sustainability of URS.
输尿管镜检查(URS)是治疗结石病患者的常用方法。这种方法的缺点之一是与购买和维修内镜设备相关的巨大资本支出。在某些情况下,这些成本可能超过收入,导致企业无利可图且难以为继。我们试图在考虑内镜维护和维修成本的情况下,描述我们的URS项目的盈利能力。
我们确定了2013财年(2013财年)在一家医院进行的所有URS病例。获取了收费、收款率以及包括年度设备维修成本在内的固定和可变成本。按病例计算了URS的净利润和盈亏平衡点。
2013财年进行的190例病例中,内镜维修总成本总计115,000美元,平均每例维修成本为605美元。绝大多数病例(94.2%)在门诊进行,每例产生净利润659美元,而住院病例则产生净亏损455美元。URS最终每例的净利润接近600美元。在盈亏平衡分析中,直到每例维修成本达到1200美元时,URS仍保持盈利。
基于这些发现,即使设备维修成本很高,已建立的URS项目仍可保持盈利能力。尽管如此,我们的研究结果强调了控制成本的重要性,特别是在当前报销减少的情况下。基于提高内镜耐用性以及探索数字和一次性平台的多方面方法,对于维持URS的可持续性至关重要。